SAN DIEGO, Sept. 15, 2015 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL), a biotechnology company developing vaccines and therapeutics for prevention and treatment of infectious diseases, today announced that the Company will present a poster summarizing results from preclinical studies of its antifungal compound, VL-2397 (formerly known as ASP2397), at the upcoming Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and the International Congress of Chemotherapy joint meeting in San Diego, California. The poster, titled "Pharmacokinetic and Pharmacodynamic Characterization of ASP2397, a Novel Potent Antifungal Agent with Activity against Invasive Pulmonary Aspergillosis," will be presented during the "New Anti-Fungal Agents" poster session on September 19, 2015 from 11:00am to 1:00pm PT.
VL-2397 is part of a potential new class of antifungal compounds for the treatment of systemic fungal infections. Systemic fungal infections are major causes of morbidity and mortality in immunocompromised patients, such as transplant recipients, in patients undergoing chemotherapy and in patients in the ICU. In preclinical studies to date, VL-2397 has demonstrated faster fungicidal activity than marketed drugs and activity against azole-resistant fungal pathogens. VL-2397 was initially developed by Astellas Pharma Inc. (TOKYO: 4503). In March 2015, Astellas granted Vical an exclusive worldwide license to develop and commercialize VL-2397. The Food and Drug Administration has granted a qualified infectious disease product (QIDP) designation to VL-2397 for the treatment of invasive aspergillosis. Vical intends to file an investigational new drug application and initiate a Phase 1 clinical trial for VL-2397 in the first half of 2016.